Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
Over 80% of patients remained relapse- and metastasis-free at 12 months after 2L dab/tram initiation, with only 2 deaths observed. Dab/tram appears to have activity in the 2L adjuvant setting, although more follow-up is required.
Authors
- Keith L. Davis (ORCID: https://orcid.org/0000-0002-0044-7107)
- Inderjit Mehmi (ORCID: https://orcid.org/0000-0002-2253-2206)
- Ryan J. Sullivan (ORCID: https://orcid.org/0000-0001-5344-6645)
- Lisanne P. Zijlker (ORCID: https://orcid.org/0000-0002-1483-0625)
- John Haanen
- Deborah Norton (ORCID: https://orcid.org/0000-0002-9840-6978)
- Jeffrey S. Weber (ORCID: https://orcid.org/0000-0002-4962-2957)
- Yana George Najjar (ORCID: https://orcid.org/0000-0002-0138-1664)
- Siddharth Karanth (ORCID: https://orcid.org/0000-0002-4923-2692)
- Waqas Haque (ORCID: https://orcid.org/0000-0001-6754-7658)
- Lucy Connolly
- Alexander C. J. van Akkooi (ORCID: https://orcid.org/0000-0002-3262-6935)
- Svetomir N. Markovic (ORCID: https://orcid.org/0000-0002-9238-4325)
- April K.S. Salama (ORCID: https://orcid.org/0000-0002-8105-5374)
- Alexander M Menzies
- Georgina V Long
- Amelia M. Taylor
Institutions
- The University of Sydney (AU)
- Duke University (US)
- Royal North Shore Hospital (AU)
- Centre Hospitalier Universitaire Vaudois (CH)
- The Netherlands Cancer Institute (NL)
- Massachusetts General Hospital (US)
- Angeles Clinic and Research Institute (US)
- Melanoma Institute Australia (AU)
- RTI Health Solutions (US)
- Mayo Clinic in Arizona (US)
- UPMC Hillman Cancer Center (US)
- Novartis (Ireland) (IE)
- Mater Hospital (GB)
- Tris Pharma (United States) (US)
- New York University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1093/oncolo/oyae289
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Hexal AG
- Array BioPharma
- Novartis Pharmaceuticals Corporation
- Moffitt Cancer Center
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- BeiGene
- Incyte
- Innovent Biologics
- Moderna
- Seagen
- Eisai
- Ipsen
- Melanoma Institute Australia
- Qbiotics
- NeraCare
- Genentech
- National Health and Medical Research Council